The Exchange has sought clarification from Natco Pharma Limited with respect to recent news item captioned Eris Lifesciences inks deal with Natco Pharma for weight-loss drug semaglutide.. The response from the Company is awaited.
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Natco Pharma to clarify a recent news article stating that Eris Lifesciences has entered into a deal with Natco Pharma for the weight-loss drug semaglutide. The news suggests a potential licensing, marketing, or distribution partnership related to the popular GLP-1 weight-loss medication. Natco Pharma has not yet issued an official response, and the exchange is awaiting confirmation or denial of the reported development. Until the company responds, the exact nature, scope, and financial terms of the deal remain unconfirmed.
This is a routine exchange clarification request and not a regulatory action. The outcome depends on Natco's response, but if a genuine partnership is confirmed, it could open a new revenue stream in the high-demand semaglutide segment; if denied, the stock may see a pullback from speculative buying.